Ameriprise
SGMO

Ameriprise’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Ameriprise’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75,274
Closed -$27K – 4006
2024
Q2 		$27K Buy
75,274
+63,800
+556% +$34.5K ﹤0.01% 3835
2024
Q1 		$7.69K Sell
11,474
-198,764
-95% -$144K ﹤0.01% 3838
2023
Q4 		$114K Buy
210,238
+127,228
+153% +$58.7K ﹤0.01% 3800
2023
Q3 		$49.8K Buy
+83,010
New +$88.9K ﹤0.01% 3836
2023
Q2 		– Sell
-26,437
Closed -$46.5K – 3996
2023
Q1 		$46.5K Sell
26,437
-42,636
-62% -$122K ﹤0.01% 3874
2022
Q4 		$217K Sell
69,073
-12,108
-15% -$47K ﹤0.01% 3687
2022
Q3 		$398K Sell
81,181
-3,582
-4% -$18.4K ﹤0.01% 3476
2022
Q2 		$351K Buy
84,763
+19,891
+31% +$86K ﹤0.01% 3517
2022
Q1 		$377K Buy
64,872
+41
+0.1% +$244 ﹤0.01% 3572
2021
Q4 		$486K Buy
64,831
+37,656
+139% +$327K ﹤0.01% 3536
2021
Q3 		$245K Sell
27,175
-204
-0.7% -$2.02K ﹤0.01% 3653
2021
Q2 		$328K Sell
27,379
-46,533
-63% -$527K ﹤0.01% 3605
2021
Q1 		$926K Sell
73,912
-66,821
-47% -$900K ﹤0.01% 3177
2020
Q4 		$2.2M Sell
140,733
-57,575
-29% -$674K ﹤0.01% 2744
2020
Q3 		$1.87M Buy
198,308
+167,607
+546% +$1.81M ﹤0.01% 2702
2020
Q2 		$275K Buy
30,701
+12,131
+65% +$113K ﹤0.01% 3391
2020
Q1 		$119K Buy
+18,570
New +$138K ﹤0.01% 3518
2018
Q2 		– Sell
-127,375
Closed -$2.42M – 3691
2018
Q1 		$2.42M Buy
+127,375
New +$2.72M ﹤0.01% 2624
2014
Q4 		– Sell
-420
Closed -$5K – 4290
2014
Q3 		$5K Buy
420
+190
+83% +$2.48K ﹤0.01% 5141
2014
Q2 		$4K Buy
230
+40
+21% +$575 ﹤0.01% 5015
2014
Q1 		$3K Hold
190
– – ﹤0.01% 4945
2013
Q4 		$3K Sell
190
-3,350
-95% -$38.6K ﹤0.01% 4776
2013
Q3 		$37K Hold
3,540
– – ﹤0.01% 3996
2013
Q2 		$27K Buy
+3,540
New +$30.9K ﹤0.01% 4093

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Ameriprise's SGMO Position: Q3 2024 in Review

Ameriprise sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 75,274 shares — an estimated $27K sold.

Ameriprise first reported a position in SGMO in Q2 2013 and held it in 24 quarters. The position peaked at $2.42M in Q1 2018. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • Ameriprise reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Ameriprise sold 75,274 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $27K.
  • Ameriprise first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 24 quarters.
  • Ameriprise's SANGAMO THERAPEUTICS INC position peaked at $2.42M in Q1 2018.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Ameriprise's 13F filing for Q3 2024, filed 14 Nov 2024.